WhiteLab Genomics: Series B

The business

WhiteLab Genomics has built an AI platform to accelerate the discovery and design of genomic therapies, including cell, RNA and DNA treatments. The company develops computationally designed bio-assets and is advancing programs toward in vivo validation. Its work connects AI-driven design with experimental validation to help create the next generation of genomic medicines.

Funding history

Oct 6, 2026Series B · This round$26M

Sources

WhiteLab Genomics raises $26 Million — AVPavpcap.com · Oct 6, 2026

Similar rounds

All Biotech rounds →

Autopoiesis Sciences

Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery.

$11MSeed · Oct 6, 2026

Sensible Biotechnologies

A platform for designing and manufacturing naturally modified mRNA medicines.

$47MSeries A · Oct 6, 2026

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026

AnaCardio

AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.

€62.5MSeries B · Sep 30, 2026

The business

Funding history

Sources

Similar rounds

Related